AndrewJacobBrennerMDPhD

Oncology • Austin, TX

Breast Cancer

Institute for Drug Development, Cancer Therapy and Research Center at UTHSCSA

Join to view full profile

Dr. Brenner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brenner's full profile

Already have an account?

Office
901 W 38th St
Ste 200
Austin, TX 78705
Phone+1 512-421-4100

Fax+1 512-451-7380

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2008
Baylor Scott & White Medical Center - Baylor College of Medicine (Temple)Residency, Internal Medicine, 2003 - 2006
Texas Tech University Health Sciences Center School of MedicineClass of 2003
University of Texas at Austin Dell Medical SchoolPh.D., Tumore Biology, 1997
Texas A&M UniversityB.S., Biochemistry, 1993

Certifications & Licensure

TX State Medical License 2005 - 2027
American Board of Internal Medicine Medical Oncology
Neuro-OncologyUnited Council for Neurologic Subspecialties

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Investigator Award Cancer Therapy and Research Center at UTHSCSA, 2012
Carmela Gigliardi Scholarship National Italian American Foundation, 2000
HEB Foundation Predoctoral Fellowship, Research Division UT MD Anderson Cancer Center, Science Park, 1993
Nestor R. Bottino Award for Aptitude and Excellence in Research Texas A&M University, 1992
Outstanding Undergraduate Biochemist Texas A&M University, 1992
Join now to see all

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer Start of enrollment: 2007 Nov 01
Unknown status
Phase 1
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab Start of enrollment: 2011 Jun 01
Completed
Phase 2
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Start of enrollment: 2013 Jun 21
COMPLETED
PHASE3
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Start of enrollment: 2013 Apr 01
Terminated
Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) Start of enrollment: 2015 Jun 03
RECRUITING
PHASE1, PHASE2
ANG1005 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2013 Oct 01
Completed
Phase 2
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases Start of enrollment: 2014 Apr 01
Completed
Phase 2
Impact of COX2 on Sera Biomarkers From Obese Subjects Start of enrollment: 2013 Oct 01
Completed
Early Phase 1
TH-302 in Combination With Bevacizumab for Glioblastoma Start of enrollment: 2015 May 01
Completed
Phase 2
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Start of enrollment: 2015 Aug 01
Completed
Phase 3
Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects Start of enrollment: 2016 Apr 01
Completed
Early Phase 1
Sacituzumab Govitecan in Recurrent Glioblastoma Start of enrollment: 2022 Jan 06
RECRUITING
PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Convection enhanced delivery of Rhenium (Re) Obisbemeda (RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial.
Andrew J Brenner, Toral Patel, Ande Bao, William T Phillips, Joel E Michalek
Nature Communications. 2025-03-07
PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomide.
Shumpei Onishi, Sridharan Jayamohan, Ashis Chowdhury, Sarah Rivas, Yoshihiro Otani
Research Square. 2025-02-10
Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy.
Jennifer Chiou, Valeria Impedovo, Yen Bao Huynh, Ruggiero Gorgoglione, Luiz O F Penalva
International Journal of Molecular Sciences. 2025-01-08

Lectures

Molecular profiling using the 92-gene assay for tumor classification of brain metastases.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Investigational Drug Doubles Survival Time for GlioblastomaMarch 12th, 2025
Researchers Develop Drug Found to More Than Double Survival Time for Glioblastoma PatientsMarch 11th, 2025
Drug Doubles Glioblastoma Survival Time in TrialMarch 7th, 2025
Join now to see all

Grant Support

Development of Potent Estrogen Receptor Beta Agonists for Treating GlioblastomaUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2023–2027
Development of Potent Estrogen Receptor Beta Agonists for Treating GlioblastomaUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2023–2027
Clinical Development of Rhenium Nanoliposomes (RNL186) for GlioblastomaUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2019–2025